The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Tempus AI, Inc. (TEM) discloses a planned sale of common stock under Rule 144 for the account of director Jennifer Doudna. The notice covers 676 shares of common stock underlying Restricted Stock Units, with an aggregate market value of $42,621.80, expected to be sold on or about September 1, 2026 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing also reports that, during the prior three months, Doudna had a separate Rule 10b5-1 sale of 2,673 shares on June 25, 2026 for $147,015.00.
Tempus AI, Inc. (TEM) officer Vanessa Kubo has given notice under Rule 144 of a proposed sale of 30,846 shares of common stock through Morgan Stanley Smith Barney LLC. The shares derive from Restricted Stock Awards originally issued on 10/14/2015. The proposed sale amount corresponds to an aggregate market value of $1,944,840.30, compared with 175,390,967 shares outstanding as of 09/01/2026. Over the past three months, Kubo has reported several Rule 10b5-1 plan sales, including 33,284 shares on 07/08/2026 for $1,910,172.09 and 23,818 shares on 08/03/2026 for $1,100,036.71, as well as smaller transactions by another insider, Ryan Fukushima.
Tempus AI, Inc. (TEM) director Nadja West reported selling 3,000 shares of Class A Common Stock on 2026-08-28 at $69.00 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 2026-05-15, and West now directly holds 31,981 shares.
Tempus AI, Inc. (symbol: TEM) is the issuer of record for a Form S-4 filing submitted to the SEC.
Tempus AI, Inc. (TEM) insider Eric P. Lefkofsky, CEO, Chairman and more than ten percent owner, reported indirect sales of 11,848 shares of Class A Common Stock on August 25, 2026, by Vas.org Foundation. The reported weighted average prices were $69.83 for 11,167 shares and $70.58 for 681 shares, executed in multiple transactions within stated price ranges. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 8, 2026.
After these transactions, Lefkofsky is reported as directly holding 2,098,130 Class A shares, and indirectly holding additional shares through several entities, including 346 Long LLC (406 shares), Lefkofsky Family 2025 GRAT (5,715,203 shares), Black Media, LLC (206 shares), and Lefkofsky Family 2026 GRAT (4,284,797 shares). The filing also notes his trustee or managerial roles in these entities and that this is the second of two Form 4s due to table line limits.
Tempus AI, Inc. (TEM) reported that entities associated with CEO and Chairman Eric P. Lefkofsky executed multiple open-market sales of Class A Common Stock on August 25, 2026. Through Gray Media, LLC, Blue Media, LLC, Lefkofsky Family Foundation and Vas.org Foundation, a total of 238,152 shares were sold in 30 transactions.
The sales were effected at weighted-average prices within ranges disclosed for each price bucket, spanning approximately the mid-$60s to low-$70s per share, and were carried out pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2026. All reported positions are held indirectly through these entities; post-transaction share balances are not provided in this part of the reporting.
Tempus AI, Inc. (TEM) is the issuer for a planned secondary sale of its Class A Common Stock by stockholder Eric Lefkofsky and related entities under Rule 144. A total of 250,000 shares are planned to be sold through J.P. Morgan Securities LLC, with an aggregate market value of $16,542,500. Tempus AI had 173,390,967 shares outstanding as of August 25, 2026. The shares to be sold were acquired via stock compensation, direct cash investments, and a prior donation transaction involving Blue Media LLC and are in addition to shares already sold by affiliated entities in the prior three months.
Tempus AI, Inc. (TEM) reported an insider transaction by a company officer. On August 21, 2026, Thomas Edward Schoenherr, who serves as CEO, Diagnostics, reported a Form 4 transaction in Class A Common Stock involving 2,694 shares at $70.00 per share, with direct holdings reported at 87,021 shares following the transaction. The transaction is coded as a sale in the form fields but uses an acquisition flag in the SEC’s direction data, and it was carried out under a Rule 10b5-1 trading plan adopted on March 3, 2026.
Tempus AI, Inc. (TEM) reported that Ryan Fukushima, CEO, Data, had an indirect sale of 14,286 shares of Class A Common Stock on August 21, 2026 at $70.00 per share, held by his spouse. After this transaction, indirect holdings by his spouse were 47,420 shares, and his direct holdings were 562,463 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by his spouse on March 12, 2026.
Tempus AI, Inc. (TEM) is the issuer for which officer Vanessa Kubo filed a Rule 144 notice to sell shares of common stock. The filing covers up to 14,286 shares to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $952,161.90 on the NASDAQ market. The form also lists prior sales in the last three months, including multiple Rule 10b5-1 sales by Vanessa Kubo and a separate sale by Ryan Fukushima.